Ocular Therapeutix Balance Sheet Health
Financial Health criteria checks 5/6
Ocular Therapeutix has a total shareholder equity of $377.7M and total debt of $67.1M, which brings its debt-to-equity ratio to 17.8%. Its total assets and total liabilities are $517.1M and $139.4M respectively.
Key information
17.8%
Debt to equity ratio
US$67.13m
Debt
| Interest coverage ratio | n/a |
| Cash | US$459.69m |
| Equity | US$377.70m |
| Total liabilities | US$139.40m |
| Total assets | US$517.09m |
Recent financial health updates
Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?
Oct 16
Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?
Oct 15Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?
Jun 30Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?
Feb 11Despite Lacking Profits Ocular Therapeutix (NASDAQ:OCUL) Seems To Be On Top Of Its Debt
Sep 09Recent updates
Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?
Oct 16Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors
Oct 11Earnings Update: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts
Aug 10Ocular Therapeutix: A Speculative Investment For Risk-Tolerant Investors
Jul 23Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stocks Shoot Up 41% But Its P/S Still Looks Reasonable
Jul 15Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Could Be 45% Below Their Intrinsic Value Estimate
Jun 05Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results
Jun 01Ocular Therapeutics' Impressive Surge: A Strategic Insight
Mar 19Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement
Feb 11Ocular Therapeutix Vies With Gene Therapies, Not Just Eylea, For Wet AMD
Jan 10Optimistic Investors Push Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Up 31% But Growth Is Lacking
Jan 09Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?
Oct 15Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?
Jun 30Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers
Mar 08Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?
Feb 11Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Are More Bearish Than They Used To Be
Nov 16Despite Lacking Profits Ocular Therapeutix (NASDAQ:OCUL) Seems To Be On Top Of Its Debt
Sep 09Ocular Therapeutix: Trading Ahead Of An Underappreciated Catalyst Event
Aug 15Financial Position Analysis
Short Term Liabilities: OCUL's short term assets ($498.6M) exceed its short term liabilities ($30.0M).
Long Term Liabilities: OCUL's short term assets ($498.6M) exceed its long term liabilities ($109.4M).
Debt to Equity History and Analysis
Debt Level: OCUL has more cash than its total debt.
Reducing Debt: OCUL's debt to equity ratio has reduced from 590.9% to 17.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OCUL has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if OCUL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.